The Food and Drug Administration on Friday approved APHEXDA, or motixafortide, in combination with filgrastim to mobilize blood-forming stem cells before autologous transplantation in adults with multiple myeloma, adding a new option to one of the most operationally important steps in modern myeloma treatment.
The FDA’s trial summary says approval was based on the randomized GENESIS study, in which 122 patients scheduled for autologous transplantation received either motixafortide plus granulocyte colony-stimulating factor, or G-CSF, or placebo plus G-CSF. The drug is intended to move hematopoietic stem and progenitor cells from bone marrow into circulating blood so they can be collected by apheresis and later returned to the patient after high-dose chemotherapy.
The key result was more successful collection in fewer procedures
In GENESIS, 92.5% of patients assigned to motixafortide plus G-CSF reached the trial’s primary stem-cell collection target within two apheresis procedures, compared with 26.2% in the placebo group, according to the peer-reviewed Nature Medicine report. The treatment also increased the proportion of patients reaching a more demanding collection threshold in a single apheresis session.
That distinction matters because stem-cell mobilization is not merely a laboratory endpoint. Patients who fail to collect enough CD34-positive cells can require additional injections, extra apheresis sessions or rescue mobilization strategies, increasing time, cost and treatment burden before transplantation can proceed.
The National Cancer Institute described the GENESIS findings earlier this year as evidence that adding motixafortide to G-CSF markedly increases the number of cells available for transplant. Autologous transplantation remains an important treatment component for eligible patients with multiple myeloma, particularly after induction therapy has reduced the burden of disease.
Motixafortide targets the CXCR4 pathway
Motixafortide is a CXCR4 antagonist. CXCR4 and its ligand CXCL12 help retain hematopoietic stem cells in the bone-marrow microenvironment. Blocking that interaction can release cells into peripheral blood, where they can be collected. The mechanism places motixafortide in the same broad mobilization strategy as plerixafor, but the new agent was developed with prolonged receptor occupancy and a dosing approach designed to produce a strong mobilization response.
The GENESIS trial, registered as NCT03246529, used a double-blind, placebo-controlled design after an initial dose-finding phase. Patients received filgrastim for four days before a single motixafortide or placebo injection, followed by apheresis. The FDA’s review focused not only on whether patients reached collection targets, but also on safety and the durability of engraftment after transplantation.
The most common adverse events reported with motixafortide were injection-site reactions, including pain, redness and itching, as well as systemic itching, flushing and back pain. The approved prescribing information also addresses hypersensitivity and other treatment risks that clinicians must consider when administering the drug.
A new mobilization option in a changing myeloma landscape
Multiple myeloma treatment has changed rapidly with combinations that include proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. Those advances have improved disease control, but they have not eliminated the logistical demands of collecting enough stem cells for autologous transplantation. Some modern induction regimens and patient characteristics can make mobilization more difficult, increasing interest in strategies that reduce failed collection.
An American Journal of Managed Care report on the approval noted that the pivotal study was built around a target of at least 6 million CD34-positive cells per kilogram within two apheresis sessions. That collection target can give transplant programs flexibility for one or more future transplant procedures and can reduce the likelihood of remobilization.
The trial also provides evidence about the quality of cells mobilized. Investigators reported that motixafortide increased populations of primitive stem and progenitor cells, an observation that may help explain the strong collection effect. At the same time, engraftment after transplantation was broadly comparable between study groups, an important check that higher mobilization did not come at the expense of transplant function.
Approval now shifts the question from efficacy to adoption
BioLineRx, the drug’s developer, is preparing a U.S. commercial launch. Company disclosures filed with the Securities and Exchange Commission describe the approval as the company’s transition into commercial-stage operations and say the launch infrastructure includes transplant-center, payer and patient-support functions.
For transplant programs, the decision will depend on more than the headline response rate. Hospitals will compare acquisition cost, reimbursement, scheduling, staff time and the expected number of apheresis sessions against existing approaches that use G-CSF alone, planned plerixafor or risk-adapted rescue strategies. The clinical advantage is most relevant when predictable collection can prevent delays or multiple procedures.
The ASCO Post summarized the approval as a new combination for stem-cell mobilization rather than a direct antimyeloma therapy. That distinction is important: APHEXDA does not replace induction chemotherapy, targeted agents or transplant itself. Its role is to improve the preparatory process that makes autologous transplantation possible.
Friday’s approval therefore addresses a narrow but consequential bottleneck in care. For patients whose treatment plan includes high-dose chemotherapy and autologous transplant, reliably collecting enough cells can determine whether the next phase proceeds on schedule. GENESIS suggests that one dose of motixafortide added to standard G-CSF can substantially improve that probability, giving transplant centers a new tool for a problem that has persisted even as the rest of myeloma therapy has advanced.
